Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3540378 in Worsening Chronic Heart Failure with Preserved Ejection Fraction
2023-505902-40-00Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing LY3540378 with Placebo (2 arms). Primary endpoint: Change from baseline in left atrial reservoir strain. Started Jan 2024; status: completed.
02
Drugs
volenrelaxin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2023-505902-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505902-40-00.